Development of a nanoparticle-based influenza vaccine using the PRINT® technology

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 4, 2013, Pages 523-531

  Galloway, Ashley L ^a   Murphy, Andrew ^a   DeSimone, Joseph M ^b,c,d   Di, Jie ^a   Herrmann, Jennifer P ^a   Hunter, Michael E ^a   Kindig, Jeffrey P ^a   Malinoski, Frank J ^a   Rumley, Megan A ^a   Stoltz, Daria M ^a   Templeman, Thomas S ^a   Hubby, Bolyn ^a  

^a Liquidia Technologies Inc   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d North Carolina State University   (United States)

Author keywords

Hemagglutinin; Influenza vaccine; Nanotechnology; PRINT; Soft lithography

Indexed keywords

HEMAGGLUTININ; IMPRINT LITHOGRAPHY; INFLUENZA VACCINES; MOLDING TECHNOLOGIES; POLY-LACTIDE-CO-GLYCOLIDE; PRINT; SOFT LITHOGRAPHY; VACCINE ADJUVANTS;

ANTIGENS; COPOLYMERS; NANOTECHNOLOGY;

VACCINES;

HEMAGGLUTININ; INFLUENZA VACCINE; NANOPARTICLE; POLYGLACTIN;

ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; FEMALE; IMMUNE SYSTEM; MALE; MEDICAL TECHNOLOGY; MOUSE; NONHUMAN; PARTICLE REPLICATION IN NONWETTING TEMPLATES; PARTICULATE MATTER;

ANIMALS; FEMALE; INFLUENZA VACCINES; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; RABBITS;

MURINAE;

EID: 84876728077     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.11.001     Document Type: Article

References (40)

1. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
2. Shahiwala A., Vyas T.K., Amiji M.M. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul 2007, 1:1-9.
3. Saroja C.H., Lakshmi P.K., Bhaskaran S. Recent trends in vaccine delivery systems: a review. Int J Pharma Investig 2011, 1:64-74.
4. Cui Z., Mumper R.J. Genetic immunization using nanoparticles engineered from microemulsion precursors. Pharm Res 2002, 19(7):939-946.
5. Wendorf J., Chesko J., Kazzaz J., Ugozzoli M., Vajdy M., O'Hagan D., et al. A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum Vaccin 2008, 4(1):44-49.
6. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Disc 2010, 9:615-627.
7. Rolland J.P., Maynor B.W., Euliss L.E., Exner A.E., Denison G.M., DeSimone J.M. Direct fabrication and harvesting of monodisperse shape-specific nanobiomaterials. J Am Chem Soc 2005, 127:10096-10100.
8. Heurtault B., Saulnier P., Pech B., Proust J.E., Benoit J.P. Physico-chemical stability of colloidal lipid particles. Biomaterials 2003, 24:4283-4300.
9. Rolland J.P., Van Dam R.M., Schorzman D.A., Quake S.R., DeSimone J.M. Solvent-resistant photocurable "liquid teflon" for microfluidic device fabrication. J Am Chem Soc 2004, 126:2322-2323.
10. Euliss L.E., DuPont J.A., Gratton S.E.A., DeSimone J.M. Imparting size, shape and composition control of materials for nanomedicine. Chem Soc Rev 2006, 35:1095-1104.
11. TM particles for the delivery of dox to HeLa cells in vitro. J Am Chem Soc 2008, 130:5008-5009.
12. Kelly J.Y., DeSimone J.M. Shape-specific monodisperse nano-molding of protein particles. J Am Chem Soc 2008, 130:5438-5439.
13. Napier M.E., DeSimone J.M. Nanoparticle drug delivery platform. Polymer Reviews 2007, 47:321-327.
14. Gratton S.E.A., Williams S.S., Napier M.E., Pohlhaus P.D., Zhou Z., Wiles K.B., et al. The pursuit of a scalable nanofabrication platform for use in material and life science. Acc Chem Res 2008, 41:1685-1695.
15. Perry J.L., Herlihy K.P., Napier M.E., DeSimone J.M. PRINT: A novel platform toward shape and size specific nanoparticle theranostics. Acc Chem Res 2011, 44(10):990-998.
16. Aguilar J.C., Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 2007, 25:3752-3762.
17. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999, 17:1075-1081.
18. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008, 26:552-561.
19. Subbarao K., Murphy B.R., Fauci A.S. Development of effective vaccines against pandemic influenza. Immunity 2006, 24:5-9.
20. Horimoto T., Kawaoka Y. Designing vaccines for pandemic influenza. Curr Top Microbiol Immunol 2009, 333:165-176.
21. Jeong W., Napier M.E., DeSimone J.M. Challenging nature's monopoly on the creation of well-defined nanoparticles. Nanomedicine 2010, 5(4):633-639.
22. Canelas D.A., Herlihy K.P., DeSimone J.M. Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery. Nanomed Nanobiotechnol 2009, 1:391-404.
23. Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council Guide for the Care and Use of Laboratory Animals 1996, National Academy Press, Washington, DC.
24. Harlow E., Lane D. Antibodies - A Laboratory Manual 1988, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press.
25. WHO Manual on Animal Influenza Diagnosis and Surveillance. (website retrieved on 05 Jan 2012). http://www.who.int/csr/resources/publications/influenza/whocdscsrncs20025rev.pdf.
26. Welch B.L. The significance of difference between two means when the population variances are unequal. Biometrika 1937, 29:350-362.
27. Milliken G.A., Johnson D.E. Analysis of messy data 1992, Chapman and Hall, London.
28. Dunnett C.W. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955, 50:1096-1121.
29. Agresti A. Categorical data analysis 2002, 211-266. John Wiley and Sons, New York. 2nd ed.
30. Uhrich K.E., Cannizzaro S.M., Langer R.S., Shakesheff K.M. Polymeric systems for controlled drug release. Chem Rev 1999, 99:3181-3198.
31. Jain J.P., Ayen W.Y., Domb A.J., Kumar N. Biodegradable polymers in drug delivery. Biodegradable Polymers in Clinical Use and Clinical Development 2011, 3-58. John Wiley and Sons, Hoboken, NJ. A.J. Domb, N. Kumar, A. Ezra (Eds.).
32. Lim T.Y., Poh C.K., Wang W. Poly (lactic-co-glycolic acid) as a controlled release delivery device. J Mater Sci Mater Med 2009, 20(8):1669-1675.
33. Sinha V.R., Trehan A. Biodegradable microspheres for parenteral delivery. Crit Rev Ther Drug Carrier Syst 2005, 22(6):535-602.
34. Stewart M.J., Plautz G.E., Del Buono L., Yang Z.Y., Xu L., Gao X., et al. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther 1992, 3:267-275.
35. San H., Yang Z.-Y., Pmopili V.J., Jaffe M.L., Plautz G.E., Xu L., et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 1993, 4:781-788.
36. Nabel G.J., Nabel E.G., Yang Z.-Y., Fox B.A., Plautz G.E., Gao X., et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993, 90:11307-11311.
37. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat Immun 2011, 12(6):509-517.
38. Davenport F.M., Hennessy A.V., Askin F.B. Lack of adjuvant effect of AIPO, on purified influenza hemagglutinin in man. J Immunol 1968, 100:1139-1140.
39. Oyewumi M.O., Kumar A., Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune response. Expert Rev Vaccines 2010, 9(9):1095-1107.
40. Squalene-based adjuvants in vaccines. (website retrieved on 05 Jan 2012). http://www.who.int/vaccine_safety/topics/adjuvants/squalene/questions_and_answers/en/.